Published in Medicine and Law Weekly, April 8th, 2005
This positive decision means there will be no change in the validity of the patent for Symbicort, covering the combination of formoterol and budesonide in Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxemburg, Monaco, the Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
AstraZeneca has a comprehensive intellectual property portfolio including both patents and data exclusivity for Symbicort. Most major European...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.